Anagrelide

Molecular formula Ci o Hy CI2 N3O Molecular weight 256.09 CAS Registry No 68475-42-3 Merck Index 13,629 

Sample preparation Mix 2 mL plasma or urine with 2 ml, 200 mM pH 7.0 phosphate buffer, extract twice with 10 mL portions of ethyl acetate. Evaporate the organic layer to dryness under a stream of nitrogen, reconstitute the residue with 60 p,L DMSO, mix, sonicate, inject a 40 jiL ahquot. 

Guard column 40 mm long ixBondapak phenyl corasU 

Mobile phase MeCN 10 mM pH 4 sodium acetate buffer 25 75 for 10 min, DMSO for 8 min, return to original mobile phase 

Pittman, K.A. Smyth, R.D. Disposition of anagrelide, an inhibitor of platelet aggregation, Clin.Pharmacol.Ther., 1981, 29, 381-386. 

---

Anagesterone acetate 2, 165 Anagrelide 244 Androstanolone 173 Anidoxime 125 Anileridine 1, 300 Anilopam T21 Anisindandione j, 147 Anitrazafen 2 ... 

CBrN 506-68-3) see Anagrelide hydrochloride Desloratadine Epinastine hydrochloride Fluoxetine Nalorphine Naloxone Pergolide cyanogen chloride... 

Anagrelide -inhibitor of platelet aggregation which causes thrombocytopenia -cardiovascular effects (CHF, edema, palpitations) -anemia -nausea and vomiting -headache... 

PDE3 cGMP-inhibited PDE cAMP cGMP cGMP, milrinone, amrinone, anagrelide, cilostazol, lixazinone, NSP-513... 

Adults The recommended starting dosage of anagrelide for adult patients is 0.5 mg 4 times daily or 1 mg 2 times daily, which should be maintained for at least 1 week. 

Absorption/Distribution - The available plasma concentration time data at steady state in patients showed that anagrelide does not accumulate in plasma after repeated administration. 

Metabolism/Excretion- Following oral administration of 14 -anagrelide in people, more than 70% of radioactivity was recovered in urine. 

Cardiovascular Use with caution in patients with known or suspected heart disease. Because of the positive inotropic effects and side effects of anagrelide, a pretreatment cardiovascular examination is recommended along with careful monitoring during treatment. 

Hepatic function impairment Exposure to anagrelide is increased 8-fold in patients with moderate hepatic impairment. Use of anagrelide in patients with severe hepatic impairment has not been studied. In patients with moderate hepatic impairment, dose reduction is required carefully monitor patients for cardiovascular effects. Pregnancy Category C. 

Mon/for/ng. Anagrelide therapy requires close clinical supervision of the patient. 

Interruption of therapy - In general, interruption of anagrelide treatment is followed by an increase in platelet count. After sudden discontinuation of therapy, the increase in platelet count can be observed within 4 days. 

CYP450 system Anagrelide enhanced the inhibition of platelet aggregation by aspirin and is an inhibitor of cyclic AMP PDE III (may exaggerate the properties of milrinone, enoximone, amrinone, olprinone, and cilostazol). 

---